The short version of triple agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-07-20. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
According to internal GM documents, the ultimate culprit appears to be operating vehicles for long periods of time with low coolant levels. The low coolant is caused by pressure caps that fail in the open position. (The new caps and recovery bottles were introduced at the same time as DEX-COOL). This exposes hot engine components to air and vapors, causing corrosion and contamination of the coolant with iron oxide particles, which in turn can aggravate the pressure cap problem as contamination holds the caps open permanently. Honda and Toyota's new extended life coolants use OAT with sebacate, but without the 2-EHA. Some added phosphates provide protection while the OAT builds up. Honda specifically excludes 2-EHA from its formulas. Typically, OAT antifreeze contains an orange dye to differentiate it from the conventional glycol-based coolants (green or yellow), though some OAT products may contain a red or mauve dye. Some of the newer OAT coolants claim to be compatible with all types of OAT and glycol-based coolants; these are typically green or yellow in color.
Carey (1940), executive officer of the American Association for the Advancement of Science and publisher of Science 1975–1987 Robert Bleiberg (1943), former publisher and managing editor of Barron's Gilman Kraft (1947), former owner and publisher of Playbill Jason Epstein (1949), editorial director of Random House and co-founder of the New York Review of Books Bernard Shir-Cliff (1949), editor of Ballantine Books and Warner Books Arthur Ochs Sulzberger (1951), publisher of The New York Times Lee Guittar (1953), former publisher of the San Francisco Examiner, The Denver Post, Dallas Times Herald, and president of USA Today Richard Goodwin Capen, Jr. (1956), former publisher of the Miami Herald; U.S. ambassador to Spain 1992–1993 Peter Mayer (1956), publisher of Overlook Press and former CEO of Penguin Books Daniel Leab (1957), historian, antiquarian and publisher book catalogues, former editor of Labor History Donald Welsh (1965), founding publisher of outdoors magazine Outside Albert Scardino (1970), publisher of The Georgia Gazette and Pulitzer Prize winner in 1984 Louis Rossetto (1971), founder and publisher of Wired magazine David Rothkopf (1977), CEO and editor of Foreign Policy magazine John R. MacArthur (1978), president and publisher of Harper's magazine, grandson of billionaire John D. MacArthur, benefactor of the MacArthur Fellows Program Jake Dobkin (1998), co-founder and publisher of Gothamist franchise
Association of Public Health Laboratories Laboratory Response Network (CDC) PulseNet (CDC) Integrated Consortium of Laboratory Networks Food Emergency Response Network Environmental Laboratory Response Network[link removed] Council to Improve Foodborne Outbreak Response
Sources: en.wikipedia.org
== Applications == ECM biomaterials are used to promote healing in a number of tissues, especially the skin and tendons. Surgimend, a collagen matrix derived from fetal bovine dermis, can trigger the healing of tendons (which do not heal spontaneously) in the ankle. This intervention can shorten healing time by almost half and allows the patient to return to full activity much sooner. Open wounds, like tendons, do not spontaneously heal and can persist for long stretches of time. When ECM biomaterials are added in multiple layers to the ulcer, the wound begins to close quickly and generates host tissue. Although preliminary studies seem promising, little information is available on the success of and direct comparisons between different ECM biomaterial devices in human trials. Alloderm, an acellular dermis derived from the skin of donated cadavers, is used in reconstructive and dental surgeries. In gingival grafts, the acellular dermis is an alternative to tissue cut from the palate of the patient's mouth. It has also been used for abdominal hernia repair, and to rebuild resected turbinates in the treatment of empty nose syndrome. Alloderm and other acellular dermal matrices are used routinely in implant based breast reconstruction after mastectomy for improved soft tissue coverage and thus decrease the risk of visible rippling, capsular contraction, implant malposition, bottoming out and implant exposure.
Curcumin incorporates a seven carbon linker and three major functional groups: an α,β-unsaturated β-diketone moiety and an aromatic O-methoxy-phenolic group. The aromatic ring systems, which are phenols, are connected by two α,β-unsaturated carbonyl groups. It is a diketone tautomer, existing in enolic form in organic solvents and in keto form in water. The diketones form stable enols and are readily deprotonated to form enolates, which bind metal ions to form acetylacetonate-like complexes. Its complexing properties are manifesting in its reaction with boric acid to give a red-colored rosocyanine. Because of its hydrophobic nature, curcumin is poorly soluble in water but is easily soluble in organic solvents. Curcumin and curcuminoids are chelators of metal ions, including iron and copper.
Human feces has historically been used as fertilizer for centuries in the form of night soil, fecal sludge, and sewage sludge. The use of untreated human feces in agriculture poses significant health risks and has contributed to widespread infection with parasitic worms—a disease called helminthiasis, affecting over 1.5 billion people in developing countries.
Sources: en.wikipedia.org
The much smaller basal phylum Xenacoelomorpha have an uncertain position within Bilateria. Animals are first represented in the fossil record in the Ediacaran period, with most modern animal phyla appearing as marine species in the Cambrian explosion, which began around 539 million years ago (Mya), and most classes during the Ordovician radiation 485.4 Mya. Common to all living animals, 6,331 groups of genes have been identified that may have arisen from a single common ancestor that lived about 650 Mya during the Cryogenian period. Historically, Aristotle divided animals into those with blood and those without. Carl Linnaeus created the first hierarchical biological classification for animals in 1758 with his Systema Naturae, which Jean-Baptiste Lamarck expanded into 14 phyla by 1809. In 1874, Ernst Haeckel divided the animal kingdom into the multicellular Metazoa (now synonymous with Animalia) and the Protozoa, single-celled organisms no longer considered animals. In modern times, the biological classification of animals relies on advanced techniques, such as molecular phylogenetics, which are effective at demonstrating the evolutionary relationships between taxa. Humans make use of many other animal species for food (including meat, eggs, and dairy products), for materials (such as leather, fur, and wool), as pets and as working animals for transportation, and services.
A germanium-68/gallium-68 generator is a device used to extract the positron-emitting isotope 68Ga of gallium from a source of decaying germanium-68. The parent isotope 68Ge has a half-life of 271.05 days and can be easily utilized for in-hospital production of 68Ga. Its decay product gallium-68 (half-life 67.84 minutes, inconvenient for transport) is extracted and used for certain positron emission tomography nuclear medicine diagnostic procedures, where the radioisotope's relatively short half-life and emission of positrons are useful for creation of 3-dimensional PET scans.
== Clinical trials == Preclinical research showed that it elicits neutralizing antibodies in non-human primates against COVID-19 variants of concern, including the SARS-CoV-2 Alpha variant, Beta variant, Delta variant, and Gamma variant.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.